Most of the reported drugs were designed to target the interaction of EFNA1-EPHA2 and overlooked other possibilities, we therefore performed molecular docking to screen for molecules directly binding to EFNA1 and examined the anti-tumor activity in ESCC. This evidence concerns the gene EPHA2 and esophageal squamous cell carcinoma.